Use of Empiric Therapeutic Anticoagulation in Critically Ill Patients With COVID-19
Researchers evaluated coagulation-linked complications in critically ill patients with COVID-19 and survival outcomes following therapeutic anticoagulation.
Researchers evaluated coagulation-linked complications in critically ill patients with COVID-19 and survival outcomes following therapeutic anticoagulation.
A multicenter team reported on the administration of COVID-19 convalescent plasma to patients with severe COVID-19 in the Yale-New Haven Health System.
Elective cancer surgery within COVID-19–free surgical pathways results in lower pulmonary complication, SARS-CoV-2 infection, and mortality rates.
Investigators assess underlying mechanisms and relevant biomarkers of morbidity and mortality due to coagulopathy in patients with severe COVID-19 infection.
In-hospital mortality rates among patients requiring mechanical ventilation were not significantly different when comparing 2 stress ulcer prophylaxis strategies: proton pump inhibitors vs histamine-2 receptor blockers.